Literature DB >> 19059160

Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection.

Manu Jain1, Maskit Bar-Meir, Susanna McColley, Joanne Cullina, Eileen Potter, Cathy Powers, Michelle Prickett, Roopa Seshadri, Borko Jovanovic, Argyri Petrocheilou, John D King, Alan R Hauser.   

Abstract

Pseudomonas aeruginosa (PA) from acute and chronic (eg, cystic fibrosis (CF)) infections differ in several respects, but they can worsen prognosis in each context. Factors that facilitate conversion from an acute to chronic phenotype are poorly understood. T3 secretion proteins are virulence factors associated with poorer outcomes in acute infections, but little is known about their role in CF. We wished to characterize T3 secretion in CF PA isolates and to examine its role in clinical outcomes. A total of 114 CF subjects were divided into 3 cohorts: 1st infected individuals, CI children, and adults. Serial respiratory cultures were analyzed for T3 secretion. Serial spirometry and exacerbation data were collected prospectively. In 1st infection, 45.2% +/- 9.1% of PA isolates secreted T3 proteins compared with 29.1% +/- 4.2% and 11.5% +/- 3.0% in CI children and CI adults, respectively (P < 0.001). An inverse correlation was observed between duration of PA infection and percent T3 positive isolates (r = -0.32, P < 0.001). Overall, no association was observed between T3 secretion and pulmonary outcomes, but in the subgroup of subjects who had at least 1 T3 positive organism, T3 secretion was inversely correlated with the forced expiratory volume in 1 s (FEV(1)) decline (r = -0.35, P = 0.02). In 1st infection, 82% of cultures grew either all or no T3-positive organisms. In these patients, T3 secretion was associated with a greater risk of subsequent PA isolation (P < 0.001). In CF, PA T3 secretion decreases with residence time in lung, may predict FEV(1) decline in patients who have detectable T3 organisms, and may facilitate persistence after 1st infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19059160      PMCID: PMC2628760          DOI: 10.1016/j.trsl.2008.10.003

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  30 in total

Review 1.  Pseudomonas aeruginosa ExoS and ExoT.

Authors:  J T Barbieri; J Sun
Journal:  Rev Physiol Biochem Pharmacol       Date:  2004-08-24       Impact factor: 5.545

2.  Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa.

Authors:  Noah Lechtzin; Majnu John; Rafael Irizarry; Christian Merlo; Gregory B Diette; Michael P Boyle
Journal:  Respiration       Date:  2005-08-17       Impact factor: 3.580

3.  Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections.

Authors:  Dao Nguyen; Pradeep K Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-22       Impact factor: 11.205

4.  Heterogeneity of biofilms formed by nonmucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Baoleri Lee; Janus A J Haagensen; Oana Ciofu; Jens Bo Andersen; Niels Høiby; Søren Molin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Identification of Pseudomonas aeruginosa genes required for epithelial cell injury.

Authors:  P J Kang; A R Hauser; G Apodaca; S M Fleiszig; J Wiener-Kronish; K Mostov; J N Engel
Journal:  Mol Microbiol       Date:  1997-06       Impact factor: 3.501

6.  Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients.

Authors:  Eric E Smith; Danielle G Buckley; Zaining Wu; Channakhone Saenphimmachak; Lucas R Hoffman; David A D'Argenio; Samuel I Miller; Bonnie W Ramsey; David P Speert; Samuel M Moskowitz; Jane L Burns; Rajinder Kaul; Maynard V Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-10       Impact factor: 11.205

7.  Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia.

Authors:  K Kurahashi; O Kajikawa; T Sawa; M Ohara; M A Gropper; D W Frank; T R Martin; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

8.  Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis.

Authors:  Manu Jain; Daniel Ramirez; Roopa Seshadri; Joanne F Cullina; Catherine A Powers; Grant S Schulert; Maskit Bar-Meir; Christine L Sullivan; Susanna A McColley; Alan R Hauser
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

9.  Intratracheal immunization with pili protein protects against mortality associated with Pseudomonas aeruginosa pneumonia in mice.

Authors:  Minoru Ohama; Kazufumi Hiramatsu; Yoshiko Miyajima; Kenji Kishi; Masaru Nasu; Jun-ichi Kadota
Journal:  FEMS Immunol Med Microbiol       Date:  2006-06

10.  Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection.

Authors:  M Feldman; R Bryan; S Rajan; L Scheffler; S Brunnert; H Tang; A Prince
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

View more
  22 in total

Review 1.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 2.  Regulation of bacterial virulence by Csr (Rsm) systems.

Authors:  Christopher A Vakulskas; Anastasia H Potts; Paul Babitzke; Brian M M Ahmer; Tony Romeo
Journal:  Microbiol Mol Biol Rev       Date:  2015-06       Impact factor: 11.056

3.  Regional Isolation Drives Bacterial Diversification within Cystic Fibrosis Lungs.

Authors:  Peter Jorth; Benjamin J Staudinger; Xia Wu; Katherine B Hisert; Hillary Hayden; Jayanthi Garudathri; Christopher L Harding; Matthew C Radey; Amir Rezayat; Gilbert Bautista; William R Berrington; Amanda F Goddard; Chunxiang Zheng; Angus Angermeyer; Mitchell J Brittnacher; Jacob Kitzman; Jay Shendure; Corinne L Fligner; John Mittler; Moira L Aitken; Colin Manoil; James E Bruce; Timothy L Yahr; Pradeep K Singh
Journal:  Cell Host Microbe       Date:  2015-08-20       Impact factor: 21.023

4.  Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.

Authors:  Carlos E Milla; James F Chmiel; Frank J Accurso; Donald R VanDevanter; Michael W Konstan; Geoffrey Yarranton; David E Geller
Journal:  Pediatr Pulmonol       Date:  2013-09-09

5.  Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentration.

Authors:  G Singh; B Wu; M S Baek; A Camargo; A Nguyen; N A Slusher; R Srinivasan; J P Wiener-Kronish; S V Lynch
Journal:  Microb Pathog       Date:  2010-06-02       Impact factor: 3.738

Review 6.  For the Greater (Bacterial) Good: Heterogeneous Expression of Energetically Costly Virulence Factors.

Authors:  Kimberly M Davis
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

Review 7.  Fitting Pieces into the Puzzle of Pseudomonas aeruginosa Type III Secretion System Gene Expression.

Authors:  Emily A Williams McMackin; Louise Djapgne; Jodi M Corley; Timothy L Yahr
Journal:  J Bacteriol       Date:  2019-06-10       Impact factor: 3.490

8.  Cheating by type 3 secretion system-negative Pseudomonas aeruginosa during pulmonary infection.

Authors:  Kamila Czechowska; Saria McKeithen-Mead; Khatoun Al Moussawi; Barbara I Kazmierczak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

9.  The AlgZR two-component system recalibrates the RsmAYZ posttranscriptional regulatory system to inhibit expression of the Pseudomonas aeruginosa type III secretion system.

Authors:  Peter J Intile; Manisha R Diaz; Mark L Urbanowski; Matthew C Wolfgang; Timothy L Yahr
Journal:  J Bacteriol       Date:  2013-11-01       Impact factor: 3.490

10.  Aminoglycoside resistance of Pseudomonas aeruginosa in cystic fibrosis results from convergent evolution in the mexZ gene.

Authors:  Michelle H Prickett; Alan R Hauser; Susanna A McColley; Joanne Cullina; Eileen Potter; Cathy Powers; Manu Jain
Journal:  Thorax       Date:  2016-06-20       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.